drugset / Trial / NCT05617664

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

NCT05617664

Unknown 150 enrolled Benha University
RandomizedParallel-groupOpen-labelTreatment

Summary

Investigators will study the efficacy and safety of mirabegron25 in treatment of primary nocturnal enuresis in comparison to oral desmopressin 120 mcg and behavioral therapy

Timeline

Start
2022-11-23
Primary completion
2023-09
Completion
2023-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desmopressin Peptide 120 ug Oral
Comparator Mirabegron Other / unclassified 25 mg Oral

Indications